The move highlights Huawei’s ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical companies are investing in modelling tools and automated laboratories to shorten development timelines and improve efficiency.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.